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Acting as hormone mimics or antagonists in the interaction with hormone receptors, endocrine disrupting
chemicals (EDCs) have the potentials of disturbing the endocrine system in sex steroid hormone-
controlled organs and tissues. These effects may lead to the disruption of major regulatory mechanisms,
the onset of developmental disorders, and carcinogenesis. Especially, among diverse EDCs, xenoestrogens
such as bisphenol A, dioxins, and di(2-ethylhexyl)phthalate, have been shown to activate estrogen
receptors (ERs) and to modulate cellular functions induced by ERs. Furthermore, they appear to be closely
related with carcinogenicity in estrogen-dependant cancers, including breast, ovary, and prostate cancers.
In  in vivo animal models, prenatal exposure to xenoestrogens changed the development of the mouse
reproductive organs and increased the susceptibility to further carcinogenic exposure and tumor
occurence in adults. Unlike EDCs, which are chemically synthesized, several phytoestrogens such as
genistein and resveratrol showed chemopreventive effects on specific cancers by contending with ER
binding and regulating normal ER action in target tissues of mice. These results support the notion that a
diet containing high levels of phytoestrogens can have protective effects on estrogen-related diseases. In
spite of the diverse evidences of EDCs and phytoestrogens on causation and prevention of estrogen-
dependant cancers provided in this article, there are still disputable questions about the dose-response
effect of EDCs or chemopreventive potentials of phytoestrogens. As a wide range of EDCs including
phytoestrogens have been remarkably increasing in the environment with the rapid growth in our
industrial society and more closely affecting human and wildlife, the potential risks of EDCs in endocrine
disruption and carcinogenesis are important issues and needed to be verified in detail.
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Chemicals known to have a potential to disrupt the
endocrine or hormone system in humans and wild animals
by affecting endocrine signals are classified as endocrine
disrupting chemicals (EDCs) [1]. Originally, EDCs are defined
by the U.S. Environmental Protection Agency (EPA) as
exogenous agents that interfere with synthesis, secretion,
transport, metabolism, binding, action or elimination of natural
blood-borne hormones that are present in the body and are
responsible for homeostasis, reproduction and developmental
process [2]. EDCs are contained in a variety of chemical classes,
including drugs, pesticides, compounds used in the plastic
industry, consumer products, industrial by-products and
pollutants, and even some naturally produced botanical
chemicals. They have been remarkably increasing in the
environment with the rapid growth in these industries [3]
and therefore, human and animals are sustainedly exposed
to a wide variety of EDCs [4]. Health effects attributed to
EDCs include a range of reproductive problems such as
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reduced fertility, male and female reproductive tract
abnormalities, skewed male/female sex ratios, loss of fetus,
and menstrual problems [5]. Specifically, EDCs have been
generally supposed to affect sex steroid hormone-controlled
organs and tissues in the reproductive tract through nuclear
hormone receptors, such as estrogen receptors (ERs), androgen
receptors (ARs), progesterone receptors (PRs) and thyroid
receptors (ThRs) [2,6]. Among these receptors, estrogen-
mimicking activities through ERs of some EDCs were first
proved to cause endocrine disruption in the 1950s and these
EDCs are generally called as ‘xenoestrogens’. Xenoestrogens
mean “foreign” estrogens having estrogenic effects on a living
organism even though they differ chemically from the
estrogenic substances internally produced by the endocrine
system of the organism. Usually, xenoestrogens may act as
false messengers and mainly disrupt the reproduction process
related with endogeneous estrogen. Diethylstilbestrol (DES),
alkylphenols (APs), bisphenol A (BPA), polychlorinated biphenyls
(PCBs) and phthalates are representative xenoestrogens having
similar structures to 17β-estradiol (E2) in EDCs. Starting in
the 1990s, extra mechanisms related with other hormonal
system were found in the endocrine disruption of industrial
compounds. For instance, the disruption of thyroid hormone
transport and the altered androgen antagonism were identified
in the actions of other EDCs [7]. As a result of the endocrine
disruption via several pathways, EDCs may cause hormone
imbalance, early puberty, brain and behavior problems,
impaired immune functions and various cancers [8]. When
it comes to cancer, E2 itself is also known as one of risk
factors in tumorigenesis of the estrogen-dependent organs,
such as endometrium, breast, and ovary [4,6]. Therefore,
xenoestrogens as estrogen mimics may increase the potential
for cancer lesions by transforming normal patterns of tissue
and interrupting dominant regulatory mechanisms in the
estrogen dependent organs. Meanwhile, unlike most chemically
synthesized EDCs, some phytoestrogens, which are produced
as secondary metabolites in some plants and act as estrogen
in animals [9,10], are known to have cancer chemopreventive
effects. According to previous reports, high level diets of
phytoestrogen may have protective effects on estrogen-related
diseases, such as prostate and breast cancers [9,11]. In this
respect, this review will focus on not only the xenoestrogenic
properties of various EDCs and their carcinogenic potentials
but the preventive effects of phytoestrogens on estrogen-
dependant cancers substantiated from the in vivo studies.
Until now, the roles of EDCs in carcinogenesis have been
reviwed mainly focusing on the causation of specific cancers
like mammary cancer by well known EDCs such as DES
and BPA [7,12,13]. But, this review will be anticipated to
provide a comprehensive point of view to understand cancer
causation and prevention by various EDCs.
EDCs have estrogen-like properties 
via ERs signaling pathway
17β-Estradiol
E2 is an endogenous female sex steroid hormone and very
important in the estrous cycle and the development of
reproductive organs in human and animals. As a hormone
binding to its receptor triggers a number of events, E2
preferentially binds to ERs. ERs are expressed in the estrogen-
dependent organs such as endometrium, breast and ovary
[14,15]. There are two forms of ERs, ERα and ERβ, which
play unique physiological roles depending on the tissue and
cell types [13]. ERs are activated by binding E2 and in turn
modulate the expression of many related genes via ERs signaling
pathways [16]. The genomic pathway is a well known classical
pathway of ERs signaling and mediates target gene regulation
via direct binding to an estrogen response element (ERE),
which is a specific DNA sequence within the promoter, of
an estrogen-ER complex [17-19]. The ERE/receptor complex
then recruits other transcription factors that are responsible
for the transcription of downstream target genes and finally
induces protein synthesis. As a result, this pathway promotes
the development of female secondary sexual characteristics
and is involved in the thickening of the endometrium and
in regulating the menstrual cycle.
Endocrine disrupting chemicals
Generally, as EDCs have similar structures to E2, they may
exhibit an estrogenic activity through the interaction with ERs
like E2. Though the binding affinities of EDCs are relatively
low compared to E2, they can activate ERs and regulate cellular
functions induced by ERs [3]. For instance, by way of the
genomic pathway, EDCs mediate the expression of many
genes through direct interaction with ERE or through interaction
with transcription factors, including members of activator
protein-1 (AP-1), nuclear factor-κB (NF-κB), signal transducer
and activator of transcription (STATs), and families of specificity
protein (SP-1), especially aryl hydrocarbon receptor (AhR),
or via modification of estrogen metabolism [2,20]. In the
previouse studies, the xenoestrogenic effects and the risks
of endocrine disruption of diverse chemicals have been
identified. The disruption effects of some well-known EDCs
on estrogen signaling pathways by their xenoestrogenic
properties are as in the following.
First, DES is a potent synthetic estrogen and a drug once
prescribed during pregnancy to prevent miscarriages orEffect of EDCs on tumor progression 267
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premature deliveries from the 1940s to 1970s [21,22] and
now classified as a representative harmful xenoestrogen by
interacting with ERs with very high affinity and influencing
genomic signaling [22,23]. Alkylphenols (APs) are common
chemicals used to make alkylphenol ethoxylate surfactants
in household detergents and personal care products and
widely used as plasticizers and chemical stabilizers in various
industries [24]. Nonylphenol (NP) and octylphenol (OP) are
typical forms of APs and easily discharged through sewage
disposal works [25]. APs bind ERα and prompt ligand-
dependent gene expression via ERE promoter. Also, APs can
reduce steroidgenesis and disrupt endocrine system via ER
indirect pathways [26,27]. While they have been used in
industry for over 40 years, the European Union has
implemented sales and use restrictions on certain applications
in which nonylphenols are used because of their alleged
“toxicity, persistence, and the liability to bioaccumulate” [28].
BPA is one of the EDCs that has been the most completely
studied. Because BPA is used in many consumer goods such
as baby bottles, beverage cans, dental sealants and other
many kinds of plastics, it has the highest opportunity to be
exposed to the environment [29]. A 2011 study that
investigated the number of chemicals pregnant women are
exposed to in the U.S. found BPA in 96% of women [30].
The binding affinity of BPA to ERs is lower than E2 or DES,
but BPA has been interacting with the ERs in a way that
is completely unique in all known classes of ER ligands. BPA
functions as a xenoestrogen by binding strongly to estrogen-
related receptor γ (ERR-γ) which is an orphan receptor
(endogenous ligand unknown) that behaves as a constitutive
activator of transcription [31]. Also, BPA has been exhibited
to interact with the ERs as a partial agonist with both AF-
1 (ligand-independent activation) and AF-2 (ligand-dependent
activation) [32,33].
Dichlorodiphenyl-trichloroethane (DDT) is one of the most
well-known synthetic pesticides and is most commonly known
among the EDCs. DDT is mainly metabolized to 1,1-dichloro-
2,2-bis(4-chlorophenyl) ethylene (DDE) and their effects have
been widely studied [34,35]. DDE can activate multiple
receptors such as ERα, AR, and PR and transcription factors
and intrude on estrogen biosynthesis by increasing an
aromatase activity, the key enzyme for catalyzing the rate-
limiting step in the transformation of androgens into estrogen
[36].
PCBs were widely used as dielectric and coolant fluids
in transformers, capacitors, and electric motors. As omnipresent
and persistant in the environment, they may cause the health
problems in humans and wildlife such as disorders in
reproductive, nervous, immune and endocrine system [37].
Concerns about the toxicity of PCBs are largely based on
the similarity in chemical structure and toxic mode of action
with dioxin. As one of EDCs, many parts of their effects are
known to be ER-mediated by acting as estrogen mimics or
as estrogen antagonists [37,38].
Phthalates are a class of chemicals widely known as
plasticizers in personal-care products, children’s toys,
pharmaceuticals, food products, and textiles and so on.
Dibutylphthalte (DBP), butyl benzyl phthalate (BBP), and di(2-
ethylhexyl)phthalate (DEHP) are typical forms of phthalates.
Recent studies report that several phthalates affect the
developmental process in animals such as a significant increase
in the number of aberrations in chromosome separations
in oocytes at anaphase in various aquatic organisms and the
alterations in gonadal development and spermatogenesis in
amphibians [39-42] and also cause the developmental
problems in human like a shortened anogenital distance among
baby boys [43]. In addition, the exposure of phthalates was
associated with mental, motor, and behavioral development
problem in children and was harmful for formation of genital
tract in both male and female [44,45]. In ligand binding assays,
phthalates were shown to weakly compete with E2 for binding
ER and to have weak ER-mediated activity [46]. In addition,
fetal male rats exposed to DBP or DEHP ostensibly showed
the deformities in androgen-dependent tissues in sexual
differentiation in vivo by a non-receptor mediated mechanism
[47].
EDCs have potential effects of 
carcinogenesis
Estrogen-dependent cancers
Regarding the carcinogenicity, previous studies of EDCs
have described that developmental exposure to xenoestrogens
can transform normal patterns of tissue, and these mutations
may interrupt dominant regulatory mechanisms and improve
the potential for cancer lesions [48,49]. Especially, the
xenoestogens can be risk factors to estrogen dependant cancers
such as breast, ovary and prostate cancers. Breast cancer
is a multifactorial disease of humans and other mammals
and is highly dependent on sex and the level of sex hormones
such as estrogen and progesterone [50]. Therefore, breast
cancer has relevance to exposure of exogeneous EDCs as
well as endogeneous hormone level. Many epidemiological
studies searched the relation between the exposure to EDCs
and breast cancer [51,52]. For instance, women exposed
to DES during pregnancy showed a modest increase in the
incidence of breast cancer risks. Daughters born after in utero
exposure to DES have shown the more development of breast268 Min-Ah Park et al.
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cancer after the age of 40 when compared to unexposed
women of the same age [53,54]. Ovarian cancer is a cancer
arising from the ovary of women and most ovarian cancers
are classified as “epithelial” believed to arise from the surface
of the ovary. For ERs in normal condition, ERβ is highly
expressed in granulose cells of the ovary, whereas ERα is
expressed at relative low levels in thecal and interstitial cells.
Several studies have reported that ERα is overexpressed in
ovarian cancer compared to normal tissue and promotes the
proliferation of cancer cells [6,55]. Prostate cancer is also
a hormone-responsive cancer developing in the male
reproductive system. Although prostate cancer is highly
dependent on adrogens, estrogens also play a role in prostate
cancer pathogenesis. ERα and ERβ are originally expressed
in different cell types in prostates; ERα is mainly expressed
in stroma and ERβ in epithelium. These two receptors are
thought to play different and opposing roles in prostate cancer
with ERα having proliferative properties and ERβ having anti-
proliferative properties [56]. But other studies suggest that
ERβ is highly expressed in the prostate and may be a susceptible
target for treating prostate cancer lesions [57,58].
Carcinogenic  effects  of  EDCs  in  in  vivo  animal
models
Generally, prenatal exposure to EDCs can change the
development of the mouse mammary gland and increase
the susceptibility to further carcinogenic exposure in the adults.
For example, mammary specific alterations due to early life
BPA exposure have been identified by several studies, in which
administrating low concentrations (25-1,000 µg/kg/day) of BPA
via subcutaneously implanted osmotic pumps have shown
the alterations to mammary gland morphology in adult animals
following perinatal exposure to BPA in mice [59]. In rats,
perinatal exposure to environmentally relevant doses of BPA
enhanced the number of intraductal hyperplasias that occurs
in adulthood, altered mammary gland morphogenesis at high
doses, and induced precancerous lesions and the development
of carcinomas in situ [60]. Exposure to BPA for 50 days in
feeding period showed an increased number of dimetylbenz
[a]anthracene (DMBA)-induced tumors per rat and a
decreased latency period compared to animals not exposed
to BPA [61]. At puberty, an enhanced sensitivity to estrogen
was shown in the mammary glands of animals exposed to
BPA, which led to increased duct lateral branching [62].
Additionally, ERα and PR overexpression was shown in the
endometrial epithelium and lamina propria of adult mice
that were exposed to BPA in uterus [63]. BPA was also shown
to enhance the expression of vascular endothelial growth
factor (VEGF) in the immature rat at 37 mg/kg of the lowest
active dose [64]. When VEGF is overexpressed, it can
contribute to cancer to grow and metastasize. Also, the vascular
permeability in uterus of ovariectomized mice was increased
by BPA [65].
For dioxins, its metabolite, 2,3,7,8-tetrachlorodibenzo-p-
dioxin (TCDD), is reported to be strongly involved in
carcinogenesis. Prenatal exposure to TCDD had shown a
significant interference in mammary gland differentiation and
morphogenesis as a greater number of terminal end buds
[66]. In mice, TCDD blocks estrogen-induced responses in
several tissues [67]. Exposure of rats to the carcinogen,
dimetylbenz[a]anthracene (DMBA), at puberty enhanced the
tumor occurrence and reduced the latency period as
compared to animals not exposed to TCDD [68,69].
DEHP , a typical phthalate, is known as a peroxisome
proliferator and a anticipated human carcinogen because it
induces 5- to 10-fold dose-related increase in liver tumor
proliferation in both sexes of rats and mice [70,71]. DEHP
was also identified to have estrogenic response in uterotrophic
and vaginal cornification assay [72]. Also, in immature
ovariectomized SD rats, DEHP caused the significant growth
in uterine weight by oral injection (20, 200 or 2,000 mg/kg) [73].
Chemopreventive effects of phytoestrogens in in
vivo animal models
Phytoestrogens are poly-phenolic non-steroidal substances
such as isoflavonodis, flavonoids, stilbenes and lignans. Many
phytoestrogens are shown to have estrogenic effects by
selectivity binding ERβ in competitive ER binding and
transcriptional assay [74]. Several animal studies showed that
phytoestrogens contended with estrogen in ERs binding and
regulated normal ERs action in target tissues [75,76]. As the
most examined phytoestrogen, genistein is an isoflavone
present in much higher quantities in human diet and in serum
when compared to endogenous estrogen, E2. Many studies
have shown that genistein is able to binding to both of the
ERs, has 20-fold expanded affinity to ERβ as compared with
ERα and has more mighty transcriptional activity in cells
transfected with ERβ [77-79]. In the respect of cancer
prevention, genistein has been shown to inhibit cell growth
in breast and prostate cancers by regulating genes responsible
for the cell proliferation, cell cycle, apoptosis, and transcriptional
regulations [12]. In the molecular level, exposure of genistein
reduced mRNA level of transforming growth factor-α (TGF-
α) and epidermal growth factor (EGF), and also reduced the
protein level of epidermal growth factor receptor (EGFR) and
vascular endothelial growth factor receptor 2 (VEGF-R2) in
the mammary gland [80,81]. As another well-known
phytoestrogen, resveratrol (3,5,4’-trihydroxy-trans-stilbene), isEffect of EDCs on tumor progression 269
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a naturally appearing phytoalexin present mainly in grapes
and therefore occurrs high levels in red wine [82,83]. This
is a compound generated by plants in reaction to
environmental stress or pathogen attack and also demonstrated
to have chemopreventive capabilites [75]. This is structurally
similar to DES and can bind to both ERα and ERβ. Also,
resveratrol reduced E2 stimulated cell growth and constrained
transcription of PR in breast cancer cell line [12,84]. But,
the antagonist activity of resveratrol is only for ERα and not
for ERβ. In mammary carcinogenesis, subcutaneous injections
of reveratrol (0, 10 or 100 mg/kg) significantly decreased NMU-
induced tumor incidence and diversity [83,85]. Also, other
studies showed that in the developing tumors of rats treated
with resveratrol, the expressions of COX-2 and matrix
metalloproteinase-9 (MMP-9) proteins had significantly
decreased [86,87]. Additionally, it was reported that in a
mammary tumorigenesis, resveratrol (1, 3 or 5 mg/kg) reduced
tumor size and angiogenesis by increasing the apoptotic
quotient in mice and rats [88,89]. While many studies support
the protective properties of phytoestrogens on cancer
formation, some studies insist their tumor progression activities.
For instance, it was reported that dietary genistein stimulated
tumor growth and antagonized the cytotoxic effects of
Tamoxifen and the aromatase inhibitor, Letrozole [90].
Resveratrol also showed detrimental effects on mammary
tumor progression [88] or no effect on the same cancer in
another study [91]. Although there is a controversy for these
mixed results, epidemiological evidences that individuals
consuming a diet high in phytoestrogens have a reduced
risk of developing various cancers and substantial experimental
outcoms are still convincing of the chemopreventive effects
of phytoestrogens.
Conclusions
Nowadays, the chemicals classified as EDCs are rapidly
Figure 1. Genomic pathways of estrogen and EDCs in ER-dependent signaling mechanisms. Estrogen and EDCs can lead to cell
proliferation in the genomic pathway in which ER dimers directly bind to EREs following ligands binding or ERs interact with other
transcription factors (TFs), including AP-1, by action of transcription factor cross-talk. EDCs can compete with estrogen in ERs
binding and induce estrogenic effects.270 Min-Ah Park et al.
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increasing in environment and therefore, human and animals
have been continually exposed to the risks of EDCs. Among
diverse EDCs, as xenoestrogens are structurally similar to E2,
an endogeneous estrogen, and act as false messengers, they
may disrupt the reproduction process related with endogeneous
estrogen. Chemically synthetic EDCs such as BPA, DDT, PCB
and phthalate are shown to act as estrogen mimics or as
antagonists by affecting ERs, ERα and ERβ, and further disturb
various cellular functions induced by ERs as shown in Figure
1. As a result, these EDCs may cause hormone imbalance,
early puberty, reproduction problems, impaired immune
functions and various cancers. In the respect of cancer, many
studies of EDCs using in vivo mouse models have described
that the exposure to xenoestrogens can transform normal
patterns of tissue, interrupt dominant regulatory mechanisms
and increase the carcinogenic potential for estrogen-
dependant cancers such as breast, ovary, endometrium and
prostate cancers. On the other hand, some EDCs have
protective effects against estrogen-related diseases. They are
mostly phytoestrogens such as genistein and resveratrol and
were shown to inhibit cell growth in breast, ovary and prostate
cancers by inducing cell cycle arrest, apoptosis, and metastasis
suppression via ER-related pathways or non ER-related
pathways. Nevertheless, as other studies suggest that
phytoestrogens also have tumorigenic properties like other
EDCs, the chemopreventive effects of phytoestrogens on
estrogen-dependant cancers are still debating.
The studies of EDCs investigated in this article sufficiently
substantiate that EDCs can be sufficient risk factors in various
reproduction problems and diseases including specific cancers,
but this assertion is somewhat controversal. This is mainly
about the validity of dosage of EDCs used in laboratory
experiments [92,93]. This is mainly about the validity of dosage
of EDCs used in laboratory experiments. Critics argue that
the concentrations of chemicals in the experiments are
relatively high and that their actual amounts in the environment
are too low to cause an endocrine disrupting effect. But,
others insist that high dosage effects are appropriate because
of EDCs’ accumulating properties in living bodies and the
environment and high frequency of exposure to EDCs [94].
Therefore, it is prerequisite to validate the effective dosage
of chemicals before elucidating their endocrine disruption
effects and risk potentials in many disorders. In addition, the
health effects of EDCs identified in in vivo studies using animal
models should be verified in huamn and other animals. Despite
the debate and need for validation, the potential risks of
EDCs in endocrine disruption and carcinogenesis are
considerbly noteworthy issues in industrialized societies.
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